← Eichor
Condition: Advanced High Grade Epithelial Ovarian Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced High Grade Epithelial Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cance
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07125391Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 · 10 location(s) · Epitopea Ltd · NCT07665515Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 · 65 location(s) · AGO Study Group · NCT05009082A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Phase 1 · 1 location(s) · Daewoong Pharmaceutical Co. LTD. · NCT07371104A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologo
Phase 2 · 10 location(s) · Oncoinvent Solutions AS · NCT06504147A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com
Phase 1/Phase 2 · 14 location(s) · AstraZeneca · NCT06188520IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa
Phase 2 · 3 location(s) · Mayo Clinic · NCT06639074Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
NA · 1 location(s) · Alexandria University · NCT06404671A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based
Phase 2 · 50 location(s) · North Eastern German Society of Gynaecological Oncology · NCT05460000A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 · 15 location(s) · IDEAYA Biosciences · NCT07503808Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 · 49 location(s) · Corcept Therapeutics · NCT06906341
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.